JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, June 5, 2022 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene…
Comments Off on JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting